Clinical Advisory Committee Established to Advance Phase 2b
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The committee comprises internationally recognized experts in stroke neurology and clinical trial design, aimed at optimizing trial parameters for success. Dr Liz Dallimore, Managing Director, emphasized the importance of this committee in enhancing the trial's design and execution. The announcement highlights Argenica's commitment to developing innovative neuroprotective therapeutics for stroke patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Presentations at European Stroke Organisation Conference
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Half Yearly Report and Accounts
- Successful Applicaton for EMA Paediatric Waiver
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Argenica Therapeutics
- IND Application Advanced With Successful Completion of Assay
- WHO Confirms Xaranetide as INN for ARG-007
- ARG007 (Xaranetide) Completes All Three FDA Requested Assays
- ARG007 Shows Significant Neuroprotection in Concussion Study
- Notification of cessation of securities - AGN
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics